ACINO GAINS COMMERCIAL RIGHTS FOR ALLECRA’S ANTIBIOTIC DRUG 

KUALA LUMPUR, June 24 (Bernama) -- Acino and Allecra Therapeutics (Allecra) have signed an exclusive licensing agreement under which Acino gains the rights to commercialise Allecra’s antibiotic drug EXBLIFEP (cefepime/enmetazobactam).

Acino has the rights to commercialise the drug within the Republic of South Africa and the member states of the Gulf Cooperation Council (GCC) alliance, which includes Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates, effective June 12.

In addition, the companies have signed a supply agreement under which Allecra will supply the cefepime/enmetazobactam finished product in that territories, according to a statement.

bootstrap slideshow

Acino Interim Chief Executive Officer, Andrew Bird said the company is incredibly excited to partner with Allecra to offer access to this innovative product in two key geographic regions and, potentially, beyond.

“We are committed to expediting the registration process in these designated markets to ensure hospitals’ swift access to EXBLIFEP as they continue to fight against high-risk infectious diseases in patients,” he said.

Meanwhile, Allecra Therapeutics Chief Financial Officer and Managing Director, Andreas Kranzusch said: “This agreement reflects the understanding that there remains a significant global need to address the dangerous increase of resistance to standard-of-care antibiotics, and we look forward to working with Acino to address this.”

bootstrap slideshow

In February, the United States (US) Food and Drug Administration (FDA) approved EXBLIFEP as a treatment for complicated urinary tract infections (cUTI), in patients 18 years and older.

Meanwhile, in March, the European Commission (EC) granted marketing authorisation for EXBLIFEP on the treatment of adult patients with cUTI; hospital-acquired pneumonia (HAP); and bacteraemia that occurs in association with, or is suspected to be associated with any of the infections listed previously.

Headquartered in Zurich, Acino is a Swiss pharmaceutical company that delivers quality pharmaceuticals to promote affordable healthcare in these emerging markets and leverage its high-quality pharmaceutical manufacturing capabilities and network to supply leading companies via contract manufacturing and out-licensing.

-- BERNAMA